Results 211 to 220 of about 5,706,732 (263)

Cancer in Systemic Sclerosis: Clinical Associations and Prognostic Impact From the EUSTAR Registry

open access: yesArthritis &Rheumatology, EarlyView.
Objective Cancer represents a major cause of death in systemic sclerosis (SSc). Established risk factors are limited to specific subsets, particularly early diffuse anti‐RNA polymerase III (POLR3)–positive disease, needing further exploration. Methods We performed a nested case‐control study within the European Scleroderma Trials and Research group ...
Antonio Tonutti   +52 more
wiley   +1 more source

Plasma Proteome Reflects Tissue Damage and Clinical Manifestations in Patients With Inflammatory Myopathies

open access: yesArthritis &Rheumatology, EarlyView.
Objective Tissue‐specific biomarkers that are reliable and associated with clinical manifestations of idiopathic inflammatory myopathy (IIM) are lacking. The blood circulation in individuals serves as a central conduit, allowing communication between tissues and facilitating clearance and recycling of tissue‐derived proteins.
Yue‐Bei Luo   +23 more
wiley   +1 more source

Expert Perspective: Toward Treat‐to‐Target Management in Adult Idiopathic Inflammatory Myopathies

open access: yesArthritis &Rheumatology, Accepted Article.
Treat‐to‐target (T2T) has transformed the management of several rheumatic diseases through predefined therapeutic goals, structured disease assessment, and timely treatment adjustment. Despite major advances in the understanding and treatment of idiopathic inflammatory myopathies (IIM), a formal T2T framework for adult IIM has not yet been established.
Shiri Keret   +2 more
wiley   +1 more source

Cognitive dysfunction in patients with interstitial lung disease. [PDF]

open access: yesFront Med (Lausanne)
Deng X   +6 more
europepmc   +1 more source

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz   +7 more
wiley   +1 more source

Interstitial lung disease in metastatic breast cancer: a landscape review using SEER-Medicare. [PDF]

open access: yesBreast Cancer Res Treat
Pinheiro LC   +4 more
europepmc   +1 more source

Overcoming intranasal delivery barriers with ultrastable polyzwitterionic siRNA nanocages for enhanced glioblastoma therapy

open access: yesBMEMat, EarlyView.
A ROS‐responsive, zwitterionic nanocage enables stable, intranasal siRNA delivery to glioblastoma, promoting deep tumor penetration via non‐degradative pathways and trigeminal nerve transport. This platform achieves durable gene silencing and tumor suppression, offering a non‐invasive, storage‐stable strategy for treating glioma and other neurological ...
Jingwen Xie   +12 more
wiley   +1 more source

Visibility of breathlessness in fibrotic interstitial lung disease: perceptions of international healthcare professionals. [PDF]

open access: yesERJ Open Res
Kalluri M   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy